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Abstract: Background: This study compared a group of 47 regular gym users who take androgenic-anabolic steroids (the 
AAS group) as part of their recreational sport, with a group of 48 regular gym users who do not use AAS (the Non-AAS 
group) on self-reports of Retrospective memory (RM), executive function (EF) and prospective memory (PM), which are 
all critical to everyday remembering. 
Methods: All participants were tested using an on-line Survey Monkey method. The Prospective and Retrospective 
Memory Questionnaire (PRMQ) assessed everyday RM and PM deficits and the Executive Function Questionnaire (EFQ) 
assessed self-reported problems in EF. A drug-use questionnaire and a mood questionnaire were also administered 
Results: After observing no between-group differences on alcohol or mood, omitting anyone who drank excessively or 
had drank recently, smoked or reported using any illegal drug, three one-way ANCOVAs (controlling for age) revealed 
that the ASS group reported significantly more RM deficits, EF deficits, and PM deficits, when compared with the Non-
ASS group. 
Conclusion: It was concluded that AAS use in a recreational sports context is associated with RM, EF and PM deficits, 
indicating that AAS use may damage everyday remembering. 
Keywords: Androgenic anabolic steroids, retrospective memory, executive function, prospective memory. 
INTRODUCTION 
 Anabolic-androgenic steroids (AAS) were firstly 
introduced to the public in 1889 by physiologist Charles E. 
Brown-Sequard when he made claims that by injecting AAS 
into his body, increases in strength, intellect, as well as a 
range of physiological benefits were noticeable [1].
 
By the 
mid-twentieth century, athletes were using ergogenic drugs 
in the form of AAS compounds in order to trim body fat and 
increase muscle size in an attempt to gain the edge over their 
rivals; although it should be noted that the prevalence of 
their use in sports varies widely [2]. Since the introduction of 
AAS, the covert use of these drugs in a sporting context has 
permeated populations of athletes, sports coaches and 
recreational users in an attempt to improve muscle mass and 
enhance sporting regimes, with some recent figures 
estimating as much as 38% of gym users taking steroids [3, 
4].
 
Along with any potential benefits AAS use might bring, 
they have also been linked with a range of physical and 
psychiatric problems. For example, skin lesions, edema, 
cardiac palpitations, cardiovascular diseases, as well as 
collateral effects such as reproductive toxicity, behavioural 
changes, hepatic and renal disorders, lowered fertility and 
sexual dysfunctions, have all been reported [5-10]. In 
addition, a range of behavioural and neuropsychiatric 
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symptoms have also been uncovered; ranging from mild 
irritation to uncontrolled aggression, hostility and violence 
against other parties (e.g. ‘Roid Rage’). At the more extreme 
end, the use of AAS has been associated in increased levels of 
depression and mania. However, the severity and frequency 
of these effects largely depend on the dose used and the 
length of time misusing AAS [11-16].
 
 In terms of cognition, only a handful of studies have 
investigated the cognitive deficits associated with the long-
term use of AAS. In one study, long-term AAS users showed 
no significant differences from a non-user comparison group 
on measures of response speed, sustained attention, and 
verbal memory. However, the AAS user group did show 
significantly reduced performance on a visuospatial memory 
task which assessed their memory for shapes and locations 
of objects [17]. In addition, a significant negative correlation 
between lifetime usage of AAS and visuospatial 
performance was observed in this study, suggesting a dose-
related impairment.
 
In a more recent study, 22 adult male 
long-term AAS users were administered 4 computerized 
tests from the Cambridge Neuropsychological Test 
Automated Battery and the Iowa Gambling Task. Analyses 
revealed selective cognitive deficits in AAS users, with 
specific deficits on cognitive measures of inhibitory control 
and attention, with no differences in terms of planning or 
decision making [18]. Taken together, these findings suggest 
there may be selective cognitive deficits associated with 
persistent AAS use. 
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 Given the scarcity of research into the cognitive deficits 
associated with AAS use in a sports context, the current 
study aims to elucidate the links between AAS use and 
cognition by focusing on 3 key cognitive processes 
important in everyday remembering. The previous work 
cited [17-18] are both examples of retrospective memory 
(RM: recall of past memory for people, words, facts, and 
events from long-term memory) [19].
 
Since both of these 
studies were carried out under laboratory conditions, it could 
be argued that they lacked ecological validity. The first aim 
of the current study was therefore to assess whether AAS use 
was associated with RM deficits in a real-world context (i.e., 
everyday tasks). The second aim was to extend our 
understanding of the cognitive deficits affected by AAS use 
by including two other key processes involved in everyday 
remembering. Executive function (EF) is an umbrella term 
used to describe a range of cognitive processes that are used 
to help co-ordinate information in memory, plan and execute 
tasks, impulse control, and attention [20].
 
For example, when 
trying to focus on two tasks simultaneously or attempting to 
concentrate on a Sudoku number game, EF resources would 
be heavily employed. Prospective memory (PM) refers to the 
process of remembering a planned action or intention at an 
appropriate time in the future - a kind of remembering to 
remember [21]. For example, remembering to meet with 
friends on time, remembering to pay a bill before a given 
deadline or monitoring when to take a medication, are tasks 
that would all be underpinned by PM resources. Both EF and 
PM are interrelated processes that are thought to be critical 
to independent living [22-25]. A compromised EF is likely to 
lead to confusion, poor planning and other executive 
problems on everyday tasks; similarly, poor PM ability leads 
to varying degrees of forgetfulness which can have relatively 
minor consequences in everyday life (e.g. feeling 
embarrassed about missing a pre-planned appointment) or 
quite serious consequences (e.g. forgetting to take an 
important medication on time can have serious health 
implications). RM, EF and PM operate together to support 
effective everyday memory functioning [22],
 
therefore, a 
compromised RM, as demonstrated by previous work [17, 
18] should also be accompanied by deficits in both EF and 
PM functions. 
AIMS 
 Developing a greater understanding of the everyday 
cognitive consequences of persistent use of AAS has merit. 
The main objective of the current study is to explore the 
relationship between AAS use and everyday memory in the 
form of RM, EF and PM functions by comparing a group of 
regular gym users who use AAS with a group of regular gym 
users who do not use AAS. The following hypothesis was 
tested: if regular use of AAS does compromise everyday 
memory then it is expected that the AAS user group should 
report more deficits in terms of their RM, EF and PM, when 
compared to a non-user group. 
MATERIALS AND METHODOLOGY 
Participants 
 An original sample of 150 individuals from varied walks 
of life was assessed via the on-line tool Survey Monkey, 
which was chosen as a method of data collection mainly due 
to its ease of use and the anonymity it provides. From this 
original sample, 55 were omitted from the analysis on the 
basis of the following exclusion criteria. 1. Given that 
females rarely use AAS [3] the current study focused on 
males only to reflect this pattern. 2. Since other drug use 
(e.g., excessive drinking - defined as drinking above 21 units 
of alcohol per week as recommended by UK Government 
health bodies, cannabis and ecstasy) have been linked to 
memory deficits independent of AAS use [26-28] anyone 
who reported having used one or more of the illegal 
substances or drinking excessively were excluded. 3. 
Anyone who reported using alcohol within the last 48 hours 
was also excluded in order to control for potential 
‘hangover’ effects confounding the results. 4. Only 
participants aged between 18-30 years were included in the 
final sample in order to reduce any age-related memory 
effects. 5. Anyone who had failed to fully complete the 
survey was also excluded. The final sample comprised 95 
participants who were regular gym users. Of these, 47 were 
regular AAS users (Mean age = 24.1 years (2.96); Mean 
occasions used per week = 2.09 (SD=0.71); Mean dose per 
occasion = 151 mg (SD=159); Days since last used = 5.82 
(SD=9.25); Years spent using AAS = 2.44 (SD=1.89) and 48 
were non-users (the Non-AAS group; Mean age = 22.4 years 
(2.98). Since mood has been known to affect everyday 
memory independent of AAS use [29, 30] this was analysed 
and compared between the two groups. Normal (non-
excessive) alcohol use per week, along with last alcohol use 
in hours and the number of years spent drinking alcohol were 
also analysed and compared between the two groups. 
Measures 
 The participants completed a series of self-reported 
questionnaires that were uploaded onto Survey Monkey 
along with a participant information sheet informing them 
about the nature of the study, a consent button which they 
would click to proceed, a full debrief sheet, advice on how to 
withdraw their data at a later date and finally contacts for 
drug helplines for those who became concerned about their 
own substance use after participation in the study were also 
included in the survey 
AAS Use and Other Drug Use 
 AAS use and other drug use (including alcohol, smoking, 
ecstasy and cannabis) were assessed by a modified version 
of the University of East London Recreational Drug Use 
Questionnaire (RDUQ) used in previous research [26-28]. 
Mood 
 Anxiety and depressive symptoms were measured using 
the Hospital Anxiety and Depression Scale (HADS) [31] 
which is a 14-item standardised self-report questionnaire. 
Seven items measured generalised anxiety symptoms and 7 
generalised depressive symptoms; with the higher score on 
the scales indicating a greater degree of symptoms reported. 
The HADS has been shown to be a valid and reliable 
measure of mood in non-clinical samples [32]. 
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Executive Function 
 The Executive Function Questionnaire (EFQ) was used 
to assess a range of executive deficits and was devised and 
validated by previous researchers [33].
 
The EFQ is 
comprised of a series of questions designed to estimate 
deficits in the main components of executive function - 
including attentional difficulties, problems in concentration, 
one’s ability of multitask, perseverance on a task, and 
impulse control. The EFQ shows high internal consistency, 
with the reliability on Cronbach’s alpha being 0.78. 
Examples of the items on the EFQ include: “Do you tend to 
“lose” your train of thoughts?” and “Do you have difficulty 
seeing through something that you have started?” For each 
item, participants responded by circling one response from a 
four-point scale (1) no problems experienced; (2) a few 
problems experienced; (3) more than a few problems 
experienced; (4) a great many problems experienced. Table 2 
contains the full list of executive questions contained in the 
EFQ. The total scale score was computed by summing the 
responses to the six items and this total score was intended to 
reflect the participant’s overall experience of executive 
problems rather than any specific aspect thereof, with a higher 
score indicating more executive deficits experienced. 
Prospective and Retrospective Memory 
 Prospective memory (PM) and retrospective memory 
(RM) were assessed using the Prospective and Retrospective 
Memory Questionnaire (PRMQ) which is a standardised 
self-report measure developed by previous researchers [34]. 
The PRMQ assesses self-reported PM and RM deficits in 
everyday life; with a higher score on these scales indicating 
more deficits reported and shows high internal consistency, 
with the reliability on Cronbach’s alpha being 0.89. On the 
PRMQ, 8 items pertain to PM (e.g., “Do you decide to do 
something in a few minutes’ time and then forget to do it?”) 
and 8 pertain to RM (e.g., “Do you repeat the same story to 
the same person on different occasions?”). The participant 
was asked to rate how often they experienced such failures on a 
5-point scale from "very often" (5) to "never" (1) by circling 
the response that best reflects their memory ability. A mean 
score for PM slips/failures was calculated, along with a mean 
score for RM slips/failures. A mean score for each scale (the 
PM and RM scales) was calculated by totalling the sum of 
scores on each scale and dividing this by the number of 
questions (8), with a higher score in both cases indicating more 
memory slips/failures. 
Procedure 
 The study protocol was approved by the Ethics 
Committee at Northumbria University in Newcastle-upon-
Tyne, England, and all subjects gave their informed approval 
before participating. The study had a between-subjects 
design, with anabolic-androgenic steroids (AAS) use and 
Non Use as the independent factor and scores on the RM, EF 
and PM as the dependent factors. In addition, the use of 
other substances known to influence cognitive performance 
(e.g., alcohol, smoking, cannabis and ecstasy) and mood 
(anxiety and depression) were also measured for potential 
inclusion as covariates. Survey Monkey was used as a 
platform onto which all the materials were uploaded. 
Participation was voluntary and each participant was tested 
individually for approximately 15 minutes. 
Statistical Analyses 
 All data were tested using the Statistical Program for the 
Social Sciences (SPSS v 21) for Windows. Descriptive 
analyses were applied to the data on age, alcohol and 
smoking indices, mood (HADS anxiety and depression 
scores), executive function scores (from the EFQ) and 
prospective memory and retrospective memory scores (from 
the PRMQ), in order to observe trends across the AAS and 
the Non-AAS groups. A series of 6 one-way analyses of 
variances (ANOVAs) were applied to the non-memory data 
to observe any between-group differences on age, alcohol 
indices (units per week, number of years drinking, and last 
alcohol use in hours), anxiety scores and depression scores. 
Three one-way analyses of co-variances (ANCOVAs: 
controlling for age) were applied to the memory data to 
observe any between-group differences on RM, EF and PM. 
A p value of <0.05 was considered significant. 
RESULTS 
 Table 1 shows the means and standard deviations across 
the AAS users and the Non-AAS group on age, alcohol 
indices, mood, RM, EF and PM. Five 1-way ANOVAs 
revealed no significant differences between the AAS and 
Non-AAS groups on alcohol use in units per week, alcohol 
use in years, alcohol last used in hours, nor in terms of 
HADS anxiety scores or HADS depression scores, however, 
there was a significant between-groups difference in terms of 
age (see Table 1 for df, F and p values). Age was therefore 
included into the main analyses on the RM, EF and PM 
scores (as a covariate) that follow. Three 1-way ANCOVAs 
(controlling for age) compared the AAS and Non-AAS 
groups on the RM, EF and PM scores. This revealed 
significant differences between the AAS and Non-AAS 
groups on retrospective memory scores (PRMQ-RM), 
executive function scores and prospective memory scores 
(PRMQ-PM) (see Table 1 for df, F and p values). Looking at 
means from Table 1 it is concluded that the AAS users 
reported significantly more retrospective memory deficits, 
executive function deficits, as well as more prospective 
memory deficits when compared with the Non-AAS group 
(Table 2). 
DISCUSSION 
 The results of the present work support the working 
hypothesis that the consumption of AAS within a sporting 
context is associated with self-reported RM deficits, EF 
deficits, PM deficits. These findings cannot be attributable to 
the use of illegal substances (e.g. cannabis, ecstasy), 
smoking, excessive alcohol use or having drunk alcohol 
recently - since anyone reporting these were excluded from 
the study. Since no between-groups differences were found 
on weekly (non-excessive) alcohol use or general mood (in 
terms of anxiety and depression scores), these too can be 
ruled out as potential confounds. It is therefore concluded 
that the use of AAS compromises everyday memory function 
- of which RM, EF and PM play important roles [22].
 
The 
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RM deficits are consistent with previous research that has 
revealed AAS-related deficits on visuospatial memory [17] 
and inhibitory control and attention [18].
 
However, to our 
knowledge, this if the first study to uncover everyday RM 
memory deficits associated with AAS use within a sporting 
context. The current study also revealed additional AAS-
related everyday memory deficits that extend to EF and PM 
function, both of which are also critical to everyday 
remembering. If the long-term outcomes of AAS use include 
impaired everyday memory (as is suggested here) then this 
could affect many spheres of life, including interpersonal, 
occupational, educational and health, given the ubiquitous 
nature of everyday remembering. 
Table 2. The full set of executive function questions used for 
the executive function questionnaire. 
 
1. Do you find it difficult to keep your attention on a particular task? 
2. Do you find yourself having problems concentrating on a task? 
3. Do you have difficulty carrying out more than one task at a time? 
4. Do you tend to "lose" your train of thoughts? 
5. Do you have difficulty seeing through something that you have started? 
6. Do you find yourself acting on "impulse"? 
 
 Given the fact that this is a relatively new area of study, a 
clear understanding of the underlying neuropsychological 
damage that might underpin such everyday memory deficits 
are far from clear. However, some recent work may throw 
some light on this subject. Animal research has shown that 
rats exposed to supra-physiological (higher than normal) 
doses of AAS over a period of time show signs of 
neurotropic unbalance and related behavioural disturbances 
in Nerve Growth Factor (NGF) levels in both the 
hippocampus and the basal forebrain of these rats [35].
 
Given 
that NGF plays a mediating role in higher brain functions 
that include learning and memory, the findings from animal 
research raises the concern that high doses of AAS within 
humans may lead to a depletion in NGF in the brain and 
result in deficits in learning and memory. Given the 
importance of the basal forebrain in producing acetylcholine 
which plays a key role in the brain’s neurotransmission 
system [36], as well as the role the hippocampus plays in 
memory consolidation [37],
 
it is feasible that the RM, EF and 
PM deficits observed in the current study may, at least in 
part, be due to a reduction in the brain neurotransmission 
and/or in the ability of the hippocampus to consolidate 
information within memory. It should be noted that this is 
only a theoretical possibility and that further work is needed 
to elucidate the links between AAS misuse, damage to NGF 
systems, and deficits in everyday memory in humans. A note 
of caution should also be considered when interpreting the 
results of the current study. Reporting bias refers to the 
likelihood that findings are published when they show 
‘positive’ outcomes, for example, when health and memory 
deficits are found in AAS users. Therefore, it is feasible that 
studies do exist that fail to show detrimental health outcomes 
or cognitive deficits associated with AAS use, but these may 
not have been published. The publication of both significant 
and non-significant finding in the field should therefore be 
encouraged in order to gain a balanced view. 
 There are a number of limitations to this study. The 
current study was based on a cohort of student gym users, 
including the AAS user group. Given that AAS users are 
likely to come from a range of social backgrounds, future 
cross-sectional research is needed in order to verify the 
findings observed in this study by comparing them with 
other user groups within society. Although self-reports of 
everyday memory provide useful insights into the 
metacognitive deficits reported with regular AAS use, 
objective measures of everyday memory should be used 
alongside self-reports in order to verify the findings 
objectively. Objectives measure of everyday memory could 
include the Cambridge Prospective Memory Test as a 
measure of PM and Verbal Fluency Tasks as a measure of 
EF. On a similar note, the use of self-reported AAS use 
could be bolstered by the use of biological assays to 
accurately measure the dose of AAS in the user group. 
Future research might also wish to assess what impact AAS 
use has upon real-world everyday memory functioning, 
embedding RM, PM and EF into an actual real-world task, 
given that if persistent AAS use does impede everyday 
memory, then it is within a real-world context that is most 
Table 1. Means and standard deviations (in brackets) comparing the AAS and Non-AAS groups on age, alcohol use in units per 
week, how long they had used alcohol in years, last alcohol use in hours, HADS Anxiety and HADS Depression scores, as 
well as the scores on PRMQ-RM, EFQ Executive Function Scores and the PRMQ-PM scores. The last 3 columns present 
the df, F and p values for each variable. 
 
 AAS Users (N=47) Non-AAS (N=48) df F p 
Age 24.1 (2.96) 22.4 (2.98) 1,93 7.20 0.008 
Alcohol per week 20.9 (18.4) 14.9 (13.5) 1,53 1.96 0.16 
Alcohol Use in Years 6.63 (2.19) 7.34 (7.02) 1,53 0.18 0.67 
Last Alcohol in Hours 196 (215) 115 (186) 1,53 2.12 0.15 
HADS Anxiety 4.40 (2.07) 4.70 (2.89) 1,93 0.34 0.55 
HADS Depression 5.95 (3.95) 4.91 (3.92) 1,93 1.65 0.20 
PRMQ RM 2.60 (0.90) 1.90 (0.60) 1,92 21.9 0.000 
EFQ 16.1 (5.13) 11.2 (5.17) 1,92 23.1 0.000 
PRMQ PM 3.40 (1.12) 2.15 (0.66) 1,92 46.9 0.000 
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likely to have a negative impact upon everyday living. 
Finally, despite the widespread knowledge about the dangers 
of using excessive doses of AAS, the number of users 
continues to rise [2, 3]. A qualitative study approach could 
be adopted to explore the motivations behind the onset of use 
of AAS and those factors that may account for the 
continuance of its use. 
CONCLUSION 
 This is the first study to observe everyday memory 
deficits associated with the use AAS in a sporting context. It 
is suggested that EF, PM and RM deficits be added to the 
growing list of neuropsychological sequelae associated with 
the persistent use of AAS. The use of AAS in a non-medical 
context is on the increase and is now seen as a major global 
health issue that requires further research and awareness. For 
example, AAS screening in high schools in the USA is on 
the increase [38]
 
and the number of AAS abuse cases 
presenting themselves at harm reduction services in the UK 
continues to rise [39].
 
These findings may have relevance to 
a whole range of groups within society, including policy 
makers, health care professionals, as well as the general 
public and users themselves. 
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